Cargando…

LGG-28. NOVEL BRAF INTRAGENIC DELETION IN A GLIOMA: A CASE REPORT OF A PEDIATRIC PATIENT

BACKGROUND: Numerous variant BRAF genetic alterations have been associated with malignancies. BRAF activating fusions/mutations are frequently present in low grade gliomas. BRAF intragenic deletions have been reported in melanoma, but have not previously been reported in gliomas. OBJECTIVE: To repor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flores, Valerie Cruz, Sutcliffe, Maxine, Geller, Thomas, Gomez, Ignacio Gonzalez, Smith, Stephanie, Stapleton, Stacie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Low Grade Glioma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715806/ http://dx.doi.org/10.1093/neuonc/noaa222.410

Ejemplares similares

LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION
por: Nobre, Liana, et al.
Publicado: (2020)

LGG-36. Analysis of BRAF-related mutations in pediatric low-grade glioma
por: Li, Shaoqun, et al.
Publicado: (2022)

LGG-18. EVEROLIMUS TREATMENT IN PEDIATRIC PATIENTS AFFECTED BY LOW-GRADE GLIOMAS (pLGG) NON-TSC, BRAF v600-WT
por: Cacchione, Antonella, et al.
Publicado: (2020)

LGG-51. BRAF ALTERATIONS IN PEDIATRIC LOW-GRADE GLIOMAS: RESULTS FROM A BRAZILIAN COHORT
por: Restine, Felipe, et al.
Publicado: (2020)

LGG-28. Rapid symptomatic improvement for a patient treated with BRAF inhibition for BRAFV600E mutated ganglioglioma
por: Cantor, Evan, et al.
Publicado: (2022)

LGG-11. INSTITUTIONAL EXPERIENCE OF BRAF TARGETING THERAPY
por: Lola, Gino Bardi, et al.
Publicado: (2020)

LGG-49. SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB + TRAMETINIB (D+T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG)
por: Bouffet, Eric, et al.
Publicado: (2020)

LGG-17. CLINICAL OUTCOME OF PEDIATRIC LOW GRADE GLIOMA WITH POSITIVE BRAF-FUSION TREATED WITH MEK INHIBITOR
por: Dennis, T L Ku, et al.
Publicado: (2021)

LGG-07. Novel CRISPR/Cas9 induced KIAA1549:BRAF fusion model for preclinical studies of pediatric gliomas
por: Patel, Krupesh, et al.
Publicado: (2022)

LGG-13. PILOCYTIC ASTROCYTOMAS WITH NOVEL BRAF FUSIONS DEMONSTRATE MAPK PATHWAY ACTIVATION
por: Chatwin, Hannah, et al.
Publicado: (2021)

LGG-53. Evaluation of KIAA-BRAF1549 fusions in pilocytic astrocytoma with clinicopathological correlation
por: Dandapath, Iman, et al.
Publicado: (2022)

LGG-12. SAFETY AND EFFICACY OF DUAL THERAPY WITH DABRAFENIB AND TRAMETINIB IN AN INFANT WITH BRAF V600E MUTANT INOPERABLE LOW GRADE GLIOMA
por: Green, Sage, et al.
Publicado: (2021)

LGG-07. IS BRAF ALTERATION OR A HISTOLOGIC ‘QUALIFIER’ A PREDICTOR OF OUTCOME IN PEDIATRIC PILOCYTIC ASTROCYTOMA?
por: Cler, Samuel J, et al.
Publicado: (2021)

LGG-03. INCIDENCE AND OUTCOME OF PEDIATRIC IDH-MUTANT GLIOMA
por: Yeo, Kee Kiat, et al.
Publicado: (2020)

LGG-32. CLINICAL OUTCOME OF PEDIATRIC GLIOMAS IN SINGLE INSTITUTION
por: Uchida, Hiroyuki, et al.
Publicado: (2020)

LGG-57. SIGNALLING MECHANISMS IN PAEDIATRIC LOW-GRADE GLIOMA
por: Patel, Ankit, et al.
Publicado: (2020)

LGG-11. Analysis of neurosurgical complications in pediatric supratentorial midline low-grade glioma – results from the German LGG studies
por: Weiß, Sarah, et al.
Publicado: (2022)

LGG-61. Cerebrospinal fluid as a source for liquid biopsy in pediatric gliomas
por: Nobre, Liana, et al.
Publicado: (2022)

LGG-08. MR Imaging of pediatric low-grade gliomas: Pretherapeutic differentiation ofBRAF V600E mutation,BRAF-Fused and Wild-Type tumors in patients without Neurofibromatosis-1
por: Trasolini, Andrew, et al.
Publicado: (2022)

LGG-46. MOLECULAR CHARACTERIZATION OF HEMISPHERIC LOW-GRADE GLIOMAS IN CHILDREN
por: Mišove, Adéla, et al.
Publicado: (2020)

LGG-13. THE CLINICAL AND MOLECULAR LANDSCAPE OF GLIOMAS IN ADOLESCENTS AND YOUNG ADULTS
por: Bennett, Julie, et al.
Publicado: (2020)

LGG-41. The clinical and molecular landscape of gliomas in adolescents and young adults
por: Bennett, Julie, et al.
Publicado: (2022)

LGG-53. PNOC001 (NCT01734512): A PHASE II STUDY OF EVEROLIMUS FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMAS (pLGG)
por: Mueller, Sabine, et al.
Publicado: (2020)

LGG-12. TRAMETINIB FOR PEDIATRIC LOW GRADE GLIOMAS: A SINGLE INSTITUTION EXPERIENCE
por: Barbour, Mustafa, et al.
Publicado: (2020)

LGG-44. PROGNOSTIC SIGNIFICANCE OF IMAGING CHARACTERISTICS IN PEDIATRIC LOW GRADE GLIOMAS
por: Baig, Muhammad, et al.
Publicado: (2020)

LGG-06. LONG-TERM OUTCOME OF NEWLY DIAGNOSED LOW GRADE GLIOMA
por: Sirachainan, Nongnuch, et al.
Publicado: (2020)

LGG-10. AN UNUSUAL PRESENTATION OF BILATERAL OPTIC NERVE GLIOMA IN CROUZON SYNDROME
por: Na, Brian, et al.
Publicado: (2021)

LGG-02. PEDIATRIC LOW-GRADE GLIOMA RISK STRATIFICATION IN THE MOLECULAR ERA
por: Hata, Jessica, et al.
Publicado: (2021)

LGG-04. Clinical and molecular characterization of metastatic pediatric low grade gliomas
por: Lindsay, Holly, et al.
Publicado: (2022)

LGG-59. Identifying hidden drivers of low-grade glioma tumor growth
por: Misek, Sean, et al.
Publicado: (2022)

LGG-20. Defining subgroups in low grade gliomas by their immune and stromal microenvironment
por: Körner, Meik, et al.
Publicado: (2022)

LGG-54. DETECTION OF THE KIAA1549-BRAF FUSION GENE IN CELLS FORMING MICROVASCULAR PROLIFERATIONS IN PILOCYTIC ASTROCYTOMA
por: Yamashita, Shinji, et al.
Publicado: (2020)

LGG-15. COMPREHENSIVE ANALYSIS OF MYB/MYB1-ALTERED GLIOMAS: A MULTI-INSTITUTIONAL EXPERIENCE OF 33 GLIOMAS
por: Moreira, Daniel, et al.
Publicado: (2021)

LGG-23. EXCELLENT CLINICAL / RADIOLOGICAL RESPONSE TO BRAF INHIBITION IN A YOUNG CHILD WITH IN-OPERABLE SUPRA-SELLAR PILOCYTIC ASTROCYTOMA
por: Chapman, Stacy, et al.
Publicado: (2020)

LGG-14. PRESENTATION CHARACTERISTICS AND TREATMENT OUTCOMES FOR PEDIATRIC OPTIC PATHWAY GLIOMAS IN QATAR
por: Maaz, Ata, et al.
Publicado: (2021)

LGG-08. TREATMENT OUTCOMES AND TOLERABILITY OF TRAMETINIB IN PROGRESSIVE CIRCUMSCRIBED LOW-GRADE GLIOMAS
por: Hanzlik, Emily, et al.
Publicado: (2021)

LGG-22. EVALUATION OF IMMUNE AND GENOMIC CHARACTERISTICS IN PEDIATRIC OPTIC NERVE GLIOMA (ONG)
por: Campbell, Ashley A, et al.
Publicado: (2020)

LGG-27. TARGETED THERAPY FOR PEDIATRIC LOW-GRADE GLIOMAS AND PLEXIFORM NEUROFIBROMAS WITH TRAMETINIB
por: Nguyen, Tiffany, et al.
Publicado: (2020)

LGG-40. Growth hormone replacement in children on therapy with Vemurafenib for Low Grade Glioma
por: Verrico, Antonio, et al.
Publicado: (2022)

LGG-54. Asthma reduces glioma formation by T cell decorin-mediated inhibition of microglia
por: Chatterjee, Jit, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6la1772il6csdq4fsqjr85nptq